CN102038747B - Compound electuary for treating faucitis - Google Patents
Compound electuary for treating faucitis Download PDFInfo
- Publication number
- CN102038747B CN102038747B CN2009103083240A CN200910308324A CN102038747B CN 102038747 B CN102038747 B CN 102038747B CN 2009103083240 A CN2009103083240 A CN 2009103083240A CN 200910308324 A CN200910308324 A CN 200910308324A CN 102038747 B CN102038747 B CN 102038747B
- Authority
- CN
- China
- Prior art keywords
- percent
- compound
- effect
- throat
- electuary
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to a Chinese patent medicament compound preparation, in particular to compound electuary for treating faucitis. The compound electuary is characterized by comprising the following components in percentage by weight: 50 to 60 percent of fig, 15 to 20 percent of weeping forsythia, 15 to 20 percent of Vietnamese sophora root, 0.1 to 0.4 percent of borneol and 4 to 5 percent of liquorice root. Proved by clinical application, the compound electuary has remarkable curative effect on acute and chronic inflammation of the throat and the upper respiratory tract, recovery of the throat after operation and auxiliary treatment of malignant tumor, has the functions of clearing heat, detoxifying, dissipating stagnation, removing blood stasis, reducing swelling, easing pain, nourishing lung, reliving a cough, relieving fire and detoxifying, meanwhile, has the effect of nourishing lung and stomach, has the advantages of good performance, low cost, no toxic or side effect and the like, and is easy to prepare.
Description
Technical field:
The present invention relates to the Chinese patent medicine compound preparation, be specifically related to a kind of treatment pharyngolaryngitis compound granules.
Background technology:
As everyone knows; Oral cavity, bottleneck throat and upper respiratory tract infection sickness rate are very high; Like acute stomatitis, ulcerative stomatitis, acute and chronic pharyngitis, acute and chronic tonsillitis, angina nosocomii, nasopharyngitis, esophagitis; Like untimely treatment, often cause the pathological changes and the general complication of adjacent organs, as: complication such as acute and chronic otitis media, sinusitis, tracheitis even pneumonia, myocarditis, rheumatic fever, urinary system infection.The external at present methods that adopt the antibiotic anti-inflammation more, drug side effect is bigger, is prone to cause the whole body complication; And state's internal therapy adopts antibiotic to be aided with heat and toxic materials clearing away medicine to be main, to cure the symptoms, not the disease more, and relapse rate is high, and side effect is big.
In addition, after oral cavity, bottleneck throat, esophagus and the upper respiratory tract operation, because of operation wound heals slower; And Chang Yinwei localized bacterial infection and influence wound healing at present, can only be used antibiotic therapy clinically; To prevent or to control inflammation, both increased patient economy burden, be prone to cause untoward reaction again.
Summary of the invention:
The present invention overcomes the defective that exists in existing throat and the oral disease therapeutic technological means, proposes a kind of heat-clearing and toxic substances removing that has, eliminating stagnation blood stasis dispelling, reducing swelling and alleviating pain, nourishing the lung to arrest cough, effects such as eliminating fire and detoxication, and the treatment pharyngolaryngitis compound granules that has no side effect
A kind of treatment pharyngolaryngitis compound granules is characterized in that comprising each component of following proportioning:
Fructus Fici 50%-60%,
Fructus Forsythiae 15%-20%,
Radix Sophorae Tonkinensis 15%-20%,
Borneolum Syntheticum 0.1%-0.4%,
Radix Glycyrrhizae 4%-5%.
The weight proportion of all kinds of raw materials is following among the present invention:
Fructus Fici 55.43%,
Fructus Forsythiae 19.96%,
Radix Sophorae Tonkinensis 19.96%,
Borneolum Syntheticum 0.22%,
Radix Glycyrrhizae 4.43%.
The Fructus Fici that the present invention adopted contains 18 seed amino acids (10 kinds essential for human body institute) and multivitamin and mineral; And have promote the production of body fluid tomorrow, drug effect such as anti-inflammation detumescence, spleen invigorating pain relieving; Fructus Fici dry fruit, mellow fruit, crude fruit with and root, stem and leaf all contain anticancer active constituent, it mainly comprises materials such as benzaldehyde, furocoumarin lactone, Psoralen, bergapton, shows that after deliberation it can improve body immunity and incidence and development that can anticancer; Simultaneously; Healthy body cell is not caused any infringement, in addition, show materials such as containing citric acid, Fumaric acid, succinic acid, malic acid, third acetic acid, oxalic acid, quininic acid in the Fructus Fici after deliberation; Has the merit of anti-inflammation detumescence, so have the effect of good relieving sore throat and diminishing swelling.Fructus Forsythiae contains forsythol, sterol compound C
49H
74-80O
6, Saponin (no hemolytic) and flavonol glycoside, horse tongue resinol glycoside etc., have significant heat-clearing and toxic substances removing, mass dissipating and swelling eliminating effect, the Fructus Forsythiae concentrated decotion has an antibacterial action external in addition, can suppress typhoid fever, Salmonella paratyphi, escherichia coli, dysentery bacterium, diphtheria corynebacterium, staphylococcus, streptococcus etc.; Especially dysentery bacterium and staphylococcus aureus are suppressed better, Radix Sophorae Tonkinensis contains matrine, oxymatrine, anagyrine and methylcytisine and all kinds of flavone components etc., has and relieves inflammation or internal heat, detoxifcation; Detumescence, analgesic curative effect, and tool antitumor action in addition; Showing after deliberation has remarkable result to malignant tumor, and side effect is little, safety; And do not make leukopenia, Borneolum Syntheticum has pain relieving and gentle antisepsis, and higher concentration (0.5%) has bacteriostasis; Can be used for neuralgia and antiinflammatory, mucosa and subcutaneous tissue all are prone to absorb, and ulcer property and stomatocace are had better curative effect; Analgesic effect is obvious, quickens inflammation and eliminates, and promotes that oral mucosa strips off, rotten to the corn and ulcer healing; Respond well to the caused mucosa infringement of physical factor especially simultaneously, and the mucosa due to antibacterial or other complicated factors is damaged, also can bring into play the auxiliary treatment effect; Radix Glycyrrhizae has antiinflammatory, anti-allergic effects, can protect the gastrointestinal mucosal and the tunica mucosa tracheae of inflammation, simultaneously some poisonous substance is had the Detoxication of similar glucuronic acid; In addition, Radix Glycyrrhizae can also have inhibitory action to the gastroxia that histamine causes, and the effect of antiacid gentle and gastrointestinal smooth muscle spasm is arranged.
The present invention proves that through clinical practice to bottleneck throat, the acute and chronic inflammation of upper respiratory tract, the auxiliary treatment of postoperative recovery of bottleneck throat and malignant tumor is evident in efficacy; Has heat-clearing and toxic substances removing, eliminating stagnation blood stasis dispelling, reducing swelling and alleviating pain; Nourishing the lung to arrest cough; The function of eliminating fire and detoxication has simultaneously the effect of supporting the lung stomach again concurrently, have performance good, remarkable advantage such as be prone to make, cost is low, have no side effect.
The specific embodiment:
A kind of treatment pharyngolaryngitis compound granules is characterized in that comprising each component of following proportioning:
Fructus Fici 50%-60%,
Fructus Forsythiae 15%-20%,
Radix Sophorae Tonkinensis 15%-20%,
Borneolum Syntheticum 0.1%-0.4%,
Radix Glycyrrhizae 4%-5%.
The weight proportion of all kinds of raw materials is following among the present invention:
Fructus Fici 55.43%,
Fructus Forsythiae 19.96%,
Radix Sophorae Tonkinensis 19.96%,
Borneolum Syntheticum 0.22%,
Radix Glycyrrhizae 4.43%.
The processing technology of the medicine that the present invention relates to adopts the traditional fabrication method, both can process electuary, also can process pill or other forms are taken; When processing electuary, at first take raw material, and mode is concocted to carry out that preorder is handled as processed etc. by said ratio; Carry out water then and carry, be i.e. decocte with water three times, each 1 hour; Collecting decoction, and concentrate, after this add qdx ethanol; Leave standstill and carried out post precipitation in 24 hours and get supernatant concentration and become cream, qinghuo reagent and sucrose, dextrin are processed granule by mixed oven dry in 1: 3: 1 again, and it is subsequent use to press every bag of packing of 20g.
The present invention has done zoopery with regard to clinical side effects and untoward reaction, selects 3 kinds of dissimilar animals to carry out the nursing of therapeutic dose respectively, observes its untoward reaction, and concrete condition is following:
1. select 20 of normal male rabbits, be divided into two groups at random: the A group is experimental group, and the B group is matched group, wherein:
The A group is fed by 0.4g/kg/d, continuous application 30d,
The B group is fed by normal nursing program.
2. select 20 of white mice, be divided into two groups at random: the A group is experimental group, and the B group is matched group, wherein:
The A group is fed by 0.3g/kg/d, continuous application 30d,
The B group is fed by normal nursing program.
3. select 10 of domesticated dogs, be divided into two groups at random: the A group is experimental group, and the B group is matched group, wherein:
The A group is fed by 0.5g/kg/d, 2-3 time/d continuous application 30d,
The B group is fed by normal nursing program.
Observe the untoward reaction situation of each two groups experiments of above three kinds of animals respectively, the result: the test group animal does not have clinical heating and gastrointestinal reaction, any side effect and untoward reaction such as anaphylaxis do not occur, explains that this medicine is safe and effective.
Prove that through clinical practice the present invention is to acute and chronic pharyngitis, acute and chronic tonsillitis, acute stomatitis, ulcerative stomatitis, angina nosocomii, nasopharyngitis, bronchitis, esophagitis; Oral cavity, bottleneck throat and esophagus and the healing of upper respiratory tract wound after surgery; In the process of the auxiliary treatment of oral cavity, bottleneck throat and esophagus and upper respiratory tract cancer, have good effect, the present invention adopts oral administering mode when clinical use, with the each 20g of electuary form, treats for 2-3 time every day, and its concrete condition is following:
Acute and chronic pharyngitis 55 examples, acute and chronic tonsillitis's 40 examples, ulcerative stomatitis 20 examples, angina nosocomii 15 examples, bronchitis 20, esophagitis 10 is totally 160 examples; Total effective rate 98%, cure rate is more than 90%.
Oral cavity, bottleneck throat and esophagus operation back 50 examples play tangible antiinflammatory, detumescence, eliminating stagnation blood stasis dispelling, the effect of reducing swelling and alleviating pain, the immediate union of promotion wound;
Auxiliary treatment 38 examples of oral cavity, bottleneck throat and esophagus and upper respiratory tract cancer, can play and promote wound immediate union and tangible analgesic effect at clinical observation March ~ 30 months.Wherein NACT 20 examples obviously alleviate the digestive tract side reaction, and appetite stimulator improves sleep, alleviates cancerous pain, and all oncosises do not have recurrent cases per capita at present.
The present invention proves that through clinical practice to bottleneck throat, the acute and chronic inflammation of upper respiratory tract, the auxiliary treatment of postoperative recovery of bottleneck throat and malignant tumor is evident in efficacy; Has heat-clearing and toxic substances removing, eliminating stagnation blood stasis dispelling, reducing swelling and alleviating pain; Nourishing the lung to arrest cough; The function of eliminating fire and detoxication has simultaneously the effect of supporting the lung stomach again concurrently, have performance good, remarkable advantage such as be prone to make, cost is low, have no side effect.
Claims (2)
1. treatment pharyngolaryngitis compound granules is characterized in that crude drug is made up of each component of following proportioning: Fructus Fici 50%-60%, Fructus Forsythiae 15%-20%, Radix Sophorae Tonkinensis 15%-20%, Borneolum Syntheticum 0.1%-0.4%, Radix Glycyrrhizae 4%-5%.
2. a kind of treatment pharyngolaryngitis compound granules according to claim 1 is characterized in that the weight proportion of all kinds of crude drug is following: Fructus Fici 55.43%, Fructus Forsythiae 19.96%, Radix Sophorae Tonkinensis 19.96%, Borneolum Syntheticum 0.22%, Radix Glycyrrhizae 4.43.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2009103083240A CN102038747B (en) | 2009-10-16 | 2009-10-16 | Compound electuary for treating faucitis |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2009103083240A CN102038747B (en) | 2009-10-16 | 2009-10-16 | Compound electuary for treating faucitis |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102038747A CN102038747A (en) | 2011-05-04 |
CN102038747B true CN102038747B (en) | 2012-03-07 |
Family
ID=43905508
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2009103083240A Expired - Fee Related CN102038747B (en) | 2009-10-16 | 2009-10-16 | Compound electuary for treating faucitis |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102038747B (en) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1260201A (en) * | 1999-09-10 | 2000-07-19 | 张发平 | Chinese preparatory medicine and its preparation method |
CN1443555A (en) * | 2002-10-29 | 2003-09-24 | 胡世英 | Medicine plaster for curing laryngopharyngitis and its preparation method |
CN1457869A (en) * | 2003-06-05 | 2003-11-26 | 桂林三金药业股份有限公司 | Chinese medicine composition for treating oral cavity and throat diseases and its preparing method |
CN1509729A (en) * | 2002-12-24 | 2004-07-07 | 汤旭雷 | Yanning adjuvant |
CN101524420A (en) * | 2008-03-06 | 2009-09-09 | 北京梅斐技术开发中心 | Chinese herbal medicament mixture for treating acute and chronic pharyngitis |
-
2009
- 2009-10-16 CN CN2009103083240A patent/CN102038747B/en not_active Expired - Fee Related
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1260201A (en) * | 1999-09-10 | 2000-07-19 | 张发平 | Chinese preparatory medicine and its preparation method |
CN1443555A (en) * | 2002-10-29 | 2003-09-24 | 胡世英 | Medicine plaster for curing laryngopharyngitis and its preparation method |
CN1509729A (en) * | 2002-12-24 | 2004-07-07 | 汤旭雷 | Yanning adjuvant |
CN1457869A (en) * | 2003-06-05 | 2003-11-26 | 桂林三金药业股份有限公司 | Chinese medicine composition for treating oral cavity and throat diseases and its preparing method |
CN101524420A (en) * | 2008-03-06 | 2009-09-09 | 北京梅斐技术开发中心 | Chinese herbal medicament mixture for treating acute and chronic pharyngitis |
Non-Patent Citations (1)
Title |
---|
黎沛环等.咽痛胶囊治疗急性咽炎、急性扁桃体炎120例.《陕西中医》.2007,第28卷(第3期), * |
Also Published As
Publication number | Publication date |
---|---|
CN102038747A (en) | 2011-05-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104013846A (en) | Traditional Chinese medicine composition for treating dental ulcer and application thereof | |
CN101972391A (en) | Medicinal composition used for treating swine mastitis and preparation method thereof | |
CN102038747B (en) | Compound electuary for treating faucitis | |
CN102961444A (en) | Compound preparation for treating rhinosinusitis | |
CN108392580A (en) | A kind of feed addictive and preparation method thereof of prevention chicken coccidiasis | |
CN101612335A (en) | Be used to Chinese medicine composition of preventing and treating mammitis of cow and preparation method thereof | |
CN107412684A (en) | A kind of stone frog tadpole inflammation medication and its preparation technology | |
CN102038822B (en) | Compound infusion for treating gastrointestinal diseases | |
CN102885929B (en) | A kind ofly treat Chinese medicine preparation of bottleneck throat inflammation and preparation method thereof | |
CN101214295B (en) | Medicament for treating chicken infectivity laryngotracheitis | |
CN104127691A (en) | Gargle for treating oral ulcer | |
CN102726625A (en) | Traditional Chinese medicine feed additive for controlling pig sarcocystosis | |
CN101700357B (en) | Traditional Chinese medicine for treating gastric ulcer | |
CN101664466A (en) | Traditional Chinese herbal composition for treating pyretic pulmonary disease of animals and preparation method thereof | |
CN102961661B (en) | Compound preparation for treating upper respiratory infection and tracheitis | |
CN103495038A (en) | Traditional Chinese medicine formula treating gastroenteric ulcers | |
CN102274292A (en) | Chinese medicine for treating gastric ulcer and duodenal ulcer | |
CN104208597A (en) | Chinese medicinal formula for treating kidney stone | |
CN104623203A (en) | Traditional-Chinese-medicine composition for treating blood-deficiency and wind-dryness type eczema | |
CN103933211A (en) | Traditional Chinese medicine decoction for treating quinsy of children | |
CN109091540A (en) | A kind of Chinese materia medica preparation and preparation method thereof for treating animal diarrhea | |
CN104415102A (en) | Traditional Chinese medicine for treating duodenal ulcer | |
CN108066423A (en) | A kind of drug for treating acute appendicitis | |
CN103006890A (en) | Ginseng-plum lozenge | |
CN106692497A (en) | Medicine for treating livestock parotitis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C17 | Cessation of patent right | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20120307 Termination date: 20121016 |